FTC To Mull Caremark Deal In PBM Insulin Pricing Case
By Matthew Perlman · March 24, 2026, 4:46 PM EDT
Federal Trade Commission staffers have asked to let the agency's commissioners consider a potential settlement with Caremark in a case accusing pharmacy benefit managers of inflating insulin prices through rebate schemes,...
To view the full article, register now.
Try a seven day FREE Trial
Already a subscriber? Click here to login